HANSEN-TECHNOLOGIES
18.1.2023 10:01:41 CET | Business Wire | Press release
Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, water, and communications industries, is pleased to announce that it is partnering with Aidon, an established, customer-centric supplier of smart grid, smart metering, and technology services in the Nordics, to provide a fully managed solution for three distribution system operators (DSOs) in the progressive Nordic market. This collaboration comes when DSOs look to enhance their infrastructure capabilities and position themselves for the changing customer market of tomorrow.
The Aidon project covers the delivery of Hansen MDM and associated services for three major DSOs: Kymenlaakson Sähköverkko, Järvi-Suomen Energia, and PKS Sähkönsiirto. A fully managed offering, it provides outsourced meter-reading and reporting capabilities for the Finnish Datahub. With this project, Hansen further bolsters its leadership position as a technology solution provider to the energy sector, delivering cost-efficient and future-ready solutions to meet emerging market demands. Among these is the ability to process real-time five-minute data reads, a crucial aspect of the evolving market regulations. With diverse energy sources such as wind and solar coming online, production and consumption data needs to be much more real-time to maintain grid balance and enable on-demand management services. Additionally, more granular data delivers greater transparency and more actionable data for end customers, especially ‘prosumers’ who also generate energy.
Hansen MDM, part of the Hansen Suite for Energy & Utilities, is a cloud-native implementation able to process large volumes of smart-metering data, and is available in a SaaS deployment model. The cloud-native version of Hansen MDM builds on decades of experience and expertise in Nordic deployments, delivering a full-featured and mature implementation for those utilities that seek the advantages of a cloud-based implementation.
Tommi Blomberg, Chief Executive Officer, Aidon, commented: "We're in the age of digitalisation and massive data generation. This partnership with one of the Nordic's longstanding technology leaders for energy and utilities will ensure that regional DSOs have access to cutting-edge solutions capable of addressing all their smart-metering needs."
Scott Weir, Division President, Energy and Utilities for the EMEA region at Hansen, commented: "At Hansen, we are proud of our legacy in the Nordic region, continually powering transformation and infrastructural enablement for several leading energy and utilities players. With our new alliance with Aidon, leveraging the best that Hansen MDM offers, we are set to bring about a new era in customer-experience innovation in the face of a rapidly changing and dynamic marketplace."
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen Technologies
Hansen Technologies (ASX: HSN) is a leading global software provider and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves 600+ customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About Aidon
Aidon is the leading provider of smart grid and smart metering solutions, applications and services in the Nordics. Our systems enable reliable metering and distribution of energy as well as efficient maintenance processes of distribution networks for our customers. The technology supplied by Aidon is in use in almost 4 million energy metering points in the Nordic countries. Our head office is in Jyväskylä, Finland, our Swedish office in Stockholm, the Norwegian office in Asker and the Danish office in Copenhagen.
For more information, visit https://www.aidon.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom